GlassScriptPhysician profile
Cheramie Rami
NPI 1720543168
$1,152.32
in general payments reported to CMS, 2019-2025
16 companies · $386 in 2025
The $386 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $128 · 2023: $300 · 2024: $339 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,025.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,024.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $375.24 | 2023-2025 | |
| Exact Sciences Corporation | $113.13 | 2023-2024 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $86.60 | 2024-2025 | Caplyta |
| Phadia US INC. | $85.76 | 2021-2025 | Immunocap |
| Astrazeneca Pharmaceuticals LP | $76.05 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Vanda Pharmaceuticals INC. | $74.63 | 2025 | Fanapt |
| Axsome Therapeutics, INC. | $72.89 | 2025 | Auvelity |
| Lilly USA, LLC | $55.11 | 2024-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.50 | 2021-2025 | Jardiance |
| Novo Nordisk INC | $40.04 | 2024 | Rybelsus, Ozempic |
| Takeda Pharmaceuticals U.S.A., INC. | $24.47 | 2021 | |
| Abbott Laboratories | $23.31 | 2024 | Freestyle Libre 3 |
| Pfizer INC. | $22.35 | 2021 | |
| Dexcom, INC. | $18.25 | 2025 | Dexcom G6 Transmitter |
| Scpharmaceuticals INC. | $17.64 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $17.35 | 2025 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheramie Rami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.